

KURARAY

K062410

Aug 16, 2006

**510(k) Summary****SEP 26 2006****3-1. 510(k) owner (submitter)**

- |                           |   |
|---------------------------|---|
| 1) Name                   | KURARAY MEDICAL INC.  |
| 2) Address                | 1621 Sakazu, Kurashiki, Okayama 710-0801, Japan   |
| 3) Contact person         | Michio Takigawa<br>Quality Assurance Department   |
| 4) Contact person in U.S. | Koji Nishida<br>KURARAY AMERICA INC.<br>600 Lexington Avenue, 26th Floor<br>New York, NY 10022<br>Tel: (212)-986-2230 (Ext. 115) or (800)-879-1676<br>Fax: (212)-867-3543 |

**3-2. Name of Device**

- |                             |   |
|-----------------------------|---|
| 1) Trade / Proprietary name | CLEARFIL ESTHETIC CEMENT & DC BOND                            |
| 2) Classification name      | Dental cement<br>(21 CFR section 872.3275. Product code: EMA) |
| 3) Common name              | Composite resin cement  |

**3-3. Predicate device**

- |                             |  |
|-----------------------------|--|
| 1) PANA VIA F 2.0           | 510(k) Number: K032455<br>Product Code: EMA<br>21 CFR Section: 872.3275<br>Applicant: KURARAY MEDICAL INC. |
| 2) CLEARFIL DC CEMENT       | 510(k) Number: K012735<br>Product Code: EMA<br>21 CFR Section: 872.3275<br>Applicant: KURARAY MEDICAL INC. |
| 3) CLEARFIL DC CORE AUTOMIX | 510(k) Number: K043177<br>Product Code: EBF<br>21 CFR Section: 872.3690<br>Applicant: KURARAY MEDICAL INC. |



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Kuraray Medical, Incorporated  
C/O Mr. Koji Nishida  
Kuraray America, Incorporated  
600 Lexington Avenue, 26<sup>th</sup> Floor  
New York, New York 10022

SEP 26 2006

Re: K062410

Trade/Device Name: Clearfil™ Esthetic Cement & DC Bond

Regulation Number: 21 CFR 872.3275(b)

Regulation Name: Dental Cement

Regulatory Class: II

Product Code: EMA

Dated: August 16, 2006

Received: August 24, 2006

Dear Mr. Nishida:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu S. Lin, PhD

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K062410

Device Name: CLEARFIL ESTHETIC CEMENT & DC BOND

### Indications for Use:

- 1) Cementation of crowns, bridges, inlays and onlays made of porcelain, ceramic, hybrid ceramics, composite resin or metal
- 2) Cementation of veneers
- 3) Cementation of adhesion bridges
- 4) Cementation of metal cores, resin cores, metal posts or glass-fiber posts

Prescription Use ✓  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use N/A  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER  
PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Susan R. Runo  
Special Sign-Off  
Division of Anesthesia, General Hospital,  
Division Control, Dental Devices  
510 Number: K062410